WHO Supports Ozempic-Like Medications for Obesity Management
Synopsis
The World Health Organization issued recommendations endorsing GLP-1 class drugs for obesity management. Published in JAMA the guidelines advise combining these treatments with lifestyle changes such as exercise and nutrition. WHO classifies obesity as a condition needing continuous management impacting one billion worldwide. Access is hindered by costs and limited availability. The patent expires next year possibly reducing its price. In Australia these drugs are subsidized for Type 2 diabetes with some individuals paying $700 a month. RACGP advocates for PBS coverage of obesity treatments. TGA issued safety alert over potential suicidal thoughts risk.
The World Health Organization released updated guidelines advising that GLP-1 medications can be prescribed as ongoing therapies for obesity. The WHO called on governments and healthcare systems globally to promptly work towards making these treatments more affordable and widely available, to all.
New recommendations published overnight in the Journal of the American Medical Association suggest that long-term GLP-1 treatments should be utilized for weight control in adults with obesity in combination with interventions, like exercise, nutrition and consistent counseling sessions.
The Effects of These Medications
GLP-1-based drugs represent a category of treatments that imitate the function of a naturally occurring hormone. They delay digestion. Promote prolonged satiety. Initially created for managing type 2 diabetes these medications have become prominent in aiding obesity control. According to the WHO its new guidelines signify a change in the approach to obesity treatment. Obesity is now acknowledged as a chronic recurring disease requiring management instead of merely a lifestyle issue.
It continues to be the leading cause of illness and premature mortality. Over one billion individuals globally face this issue and its prevalence is increasing in every nation, around the globe. Within the year 3.7 million fatalities have been attributed to non-communicable diseases linked to obesity. As stated by WHO the global economic burden of this was predicted to amount to $US3 trillion by 2030.
Professionals Appreciate the Acknowledgment
Peter Shepherd is Professor of Molecular Medicine & Pathology at the University of Auckland. He said that the article put the main emphasis on the recognition of treatments as the key way for controlling the condition of being overweight. Over the century the world has shifted from a scenario where widespread malnutrition was the primary global health issue to one where excess weight is now predominant, he noted.
A significant obstacle to successfully addressing obesity has been the lack of comprehension of the biology behind regulation and fat storage. This has transformed significantly. We now recognize that medications imitating a natural hormone named GLP-1 can safely and efficiently decrease appetite and body weight.
Expense Continues to Be an Obstacle
The JAMA article reported that significant expenses, restricted manufacturing abilities and supply-chain limitations continue to pose hurdles to global availability of GLP-1 treatments. The WHO remarked that achieving this would require collaboration between private sectors. Additionally it noted that the global patent for semaglutide marketed as Ozempic or Wegovy starts to expire in countries next year.
Shepherd mentioned that this would increase the accessibility of the drugs. He indicated that cost is a concern. Although numerous individuals note reductions in food expenses while using these medications it still remains too expensive for many.
The positive aspect is that the patent for the component will expire soon and numerous rivals are ready to enter the market so prices are expected to drop. Another concern is the long-term side effects. It is already understood that muscle deterioration due to these medications is a concern, especially in the elderly thus close observation will be necessary.
Australian Access Limited
Various GLP-1 drugs are authorized in Australia for use in either diabetes management or long-term weight control. However they receive Pharmaceutical Benefits Scheme subsidies for specific Type 2 diabetes treatments, which results in some individuals paying up to $700 monthly for these prescriptions out of pocket. The Royal Australian College of General Practitioners has advocated for these medications to be PBS-subsidised for obesity contending that this would lessen health disparities and eliminate a financial obstacle, for numerous Australians.
On Monday the Therapeutic Goods Administration released a safety warning regarding the risk of suicidal thoughts and behaviors in individuals using GLP-1 based medications, such, as Ozempic and Wegovy.
To stay on top of more health news and medical breakthroughs, visit Inspirepreneur Magazine. Keep up to date with treatments that are giving hope and changing lives all over the world.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
You Might Also Like
Berkshire Hathaway’s $1 Trillion Milestone and Strategic Moves
Nvidia China Sales Hit by US Chip Ban as CEO Visits Beijing
